Partnership Aims to Take Advantage of Preclinical Ophthalmology Developments

Rafal Farjo, PhD, COO of eyecro, told that the “demand for ophthalmology studies is increasing.  Many research scientists are uncovering new mechanisms and targets for ophthalmic disease, it is also becoming apparent that there is pathology in common with many other clinical indications.  

eyecro specializes in ophthalmic studies of preclinical efficacy, pharmacokinetics, toxicology, and topical/eyedrop formulation development.  Efficacy models include laser induce choroidal neovascularization (Laser CNV), streptozotocin-induced diabetes, intraocular ischemia/reperfusion injury, and the SKS CEP-induced Dry AMD model.

Read the entire article here.

Similar Posts